Arkolith/Insider Trading/RNTX/Form 4

Windsor James Brian

See Remarks, DirectorRein Therapeutics, Inc. (RNTX) · full profile →Form 4 · filed May 13, 2026
Net Buying
Open-Market Buys
$25K
Open-Market Sells
$0
Net Open-Market Flow
$25K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 30, 2026Buy(P)25K$1.00$25K27K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 8, 2026Grant(A)150K—$0150K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-220718) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML